Search results
Showing 3101 to 3150 of 4091 results for patient
In development Reference number: GID-TA11804 Expected publication date: 08 October 2026
Awaiting development Reference number: GID-TA11686 Expected publication date: TBC
In development Reference number: GID-TA11687 Expected publication date: TBC
Fetal vesico–amniotic shunt for lower urinary tract outflow obstruction (HTG129)
Evidence-based recommendations on fetal vesico–amniotic shunt for lower urinary tract outflow obstruction. This involves inserting a cannula through the mother's abdominal and uterine walls into the amniotic cavity and subsequently into the bladder of the fetus.
View recommendations for HTG129Show all sections
Sections for HTG129
treatment of chronic diabetic macular oedema. This should focus on a group of patients whose condition is unresponsive to other...
In development Reference number: GID-TA11372 Expected publication date: TBC
Awaiting development Reference number: GID-TA11216 Expected publication date: TBC
Awaiting development Reference number: GID-TA11219 Expected publication date: TBC
In development Reference number: GID-TA11199 Expected publication date: TBC
Pembrolizumab with chemoradiotherapy for untreated unresectable oesophageal cancer [ID6270]
Awaiting development Reference number: GID-TA11303 Expected publication date: TBC
Eneboparatide for treating chronic hypoparathyroidism [ID6532]
In development Reference number: GID-TA11688 Expected publication date: TBC
In development Reference number: GID-TA11760 Expected publication date: TBC
Nivolumab with ipilimumab for untreated advanced hepatocellular carcinoma [ID6239]
In development Reference number: GID-TA11116 Expected publication date: 29 July 2026
In development Reference number: GID-IPG10392 Expected publication date: TBC
Awaiting development Reference number: GID-TA10972 Expected publication date: TBC
In development Reference number: GID-TA11749 Expected publication date: 10 June 2027
In development Reference number: GID-TA11693 Expected publication date: TBC
In development Reference number: GID-TA11660 Expected publication date: TBC
Awaiting development Reference number: GID-TA11670 Expected publication date: TBC
In development Reference number: GID-TA11308 Expected publication date: TBC
In development Reference number: GID-TA11094 Expected publication date: TBC
In development Reference number: GID-TA11842 Expected publication date: TBC
In development Reference number: GID-TA11650 Expected publication date: TBC
Tislelizumab with chemoradiation for treating localised oesophageal squamous cell cancer [ID5077]
Awaiting development Reference number: GID-TA10971 Expected publication date: TBC
In development Reference number: GID-TA11773 Expected publication date: TBC
Awaiting development Reference number: GID-TA11747 Expected publication date: 14 April 2027
Further research, which could be registry data, should report details of patient selection, device selection, technique used, procedural...
impact on patients' lives We look back on the guidance we've produced in 2025. Podcasts 17 December 2025 Getting medicines to NHS...
HIV testing: increasing uptake among people who may have undiagnosed HIV (NG60)
This guideline covers how to increase the uptake of HIV testing in primary and secondary care, specialist sexual health services and the community. It describes how to plan and deliver services that are tailored to the local prevalence of HIV, promote awareness of HIV testing and increase opportunities to offer testing to people who may have undiagnosed HIV.
This guideline covers support for disabled children and young people with severe complex needs, from birth to 25 years. It aims to encourage education, health and social care services to work together and provide more coordinated support to children and young people, and their families and carers.
Show all sections
Sections for NG213
- Overview
- Recommendations on support for all disabled children and young people with severe complex needs
- Recommendations on specialist support for disabled children and young people with particular needs
- Recommendations on service organisation, integration and commissioning
- Terms used in this guideline
- Recommendations for research
- Rationale and impact for recommendations on supporting all disabled children and young people with severe complex needs
- Rationale and impact for recommendations on specialist support for disabled children and young people with particular needs
This quality standard covers the management of acute upper gastrointestinal bleeding in adults and young people (aged 16 and over). It describes high-quality care in priority areas for improvement.
View quality statements for QS38Show all sections
Sections for QS38
- Quality statements
- Quality statement 1: Risk assessment
- Quality statement 2: Immediate endoscopy for people who are haemodynamically unstable
- Quality statement 3: Endoscopy within 24 hours for people who are haemodynamically stable
- Quality statement 4: Endoscopic treatment for non-variceal bleeding
- Quality statement 5: Treatment of non-variceal bleeding after first or failed endoscopic treatment
- Quality statement 6: Prophylactic antibiotic therapy for variceal bleeding
- Quality statement 7: Band ligation for oesophageal variceal bleeding
New hope for people with breathing condition, COPD, as NICE approves innovative treatment
Breakthrough therapy reduces flare-ups by almost a third and could ease pressure on NHS hospitals.
Palliative photodynamic therapy for advanced oesophageal cancer (HTG132)
Evidence-based recommendations on palliative photodynamic therapy for treating advanced oesophageal cancer. This involves injecting a photosensitising agent into the tumour and using light to activate it and destroy the tumour cells.
View recommendations for HTG132Show all sections
Sections for HTG132
Eplontersen for treating hereditary transthyretin-related amyloidosis (TA1020)
Evidence-based recommendations on eplontersen (Wainzua) for treating hereditary transthyretin-related amyloidosis in adults.
Hepatocellular carcinoma (unresectable, untreated) - tislelizumab [ID6129]
Awaiting development Reference number: GID-TA11218 Expected publication date: TBC
Awaiting development Reference number: GID-TA11500 Expected publication date: TBC
Bifikafusp alfa–onfekafusp alfa for neoadjuvant treatment of 3B or 3C resectable melanoma [ID6384]
Awaiting development Reference number: GID-TA11458 Expected publication date: TBC
Acalabrutinib with venetoclax and obinutuzumab for untreated chronic lymphocytic leukaemia [ID6156]
Awaiting development Reference number: GID-TA11087 Expected publication date: TBC
Awaiting development Reference number: GID-TA11758 Expected publication date: TBC
Awaiting development Reference number: GID-TA11639 Expected publication date: TBC
Awaiting development Reference number: GID-TA11659 Expected publication date: 13 May 2027
Nipocalimab for treating warm autoimmune haemolytic anaemia [ID6642]
Awaiting development Reference number: GID-TA11855 Expected publication date: TBC
Awaiting development Reference number: GID-TA11624 Expected publication date: TBC
This quality standard covers the routine antenatal care that women and their babies should receive during pregnancy. It describes high-quality care in priority areas for improvement.
View quality statements for QS22Show all sections
Sections for QS22
- Quality statements
- Quality statement 1: Access to antenatal care
- Quality statement 2: Risk assessment
- Quality statement 3: Continuity of carer
- Quality statement 4: Vaccination
- Quality statement 5: Referral for stop-smoking support and treatment
- Quality statement 6: Healthy eating in pregnancy
- Update information
The MIST Therapy system for the promotion of wound healing (HTG267)
Evidence-based recommendations on the MIST Therapy system for the promotion of wound healing.
This quality standard covers identifying and managing familial hypercholesterolaemia (FH) in children, young people and adults. FH is a type of high cholesterol that runs in families and increases the risk of heart disease. The quality standard describes high-quality care in priority areas for improvement.
View quality statements for QS41Show all sections
Sections for QS41
- Quality statements
- Quality statement 1: Diagnosis
- Quality statement 2: Specialist referral
- Quality statement 3: DNA testing
- Quality statement 4: Diagnosis in children under 10 years
- Quality statement 5: Cascade testing
- Quality statement 6: Drug treatment in adults
- Quality statement 7: Drug treatment in children
Low back pain and sciatica in over 16s: assessment and management (NG59)
This guideline covers assessing and managing low back pain and sciatica in people aged 16 and over. It outlines physical, psychological, pharmacological and surgical treatments to help people manage their low back pain and sciatica in their daily life. The guideline aims to improve people’s quality of life by promoting the most effective forms of care for low back pain and sciatica.
This guidance has been updated and replaced by NICE guideline CG172.
by psychologists because this is considered important for achieving good patient outcomes. Taking into account the clinical and economic...
by psychologists because this is considered important for achieving good patient outcomes. Taking into account the clinical and economic...